{"id":"amodiaquine-artesunate-asaq","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amodiaquine inhibits heme polymerization in the malaria parasite's digestive vacuole, while artesunate generates reactive oxygen species that damage parasite proteins and DNA. The combination provides rapid parasite clearance (artesunate) followed by sustained suppression (amodiaquine), reducing treatment duration and improving efficacy against drug-resistant strains.","oneSentence":"ASAQ is a fixed-dose combination of amodiaquine (a 4-aminoquinoline) and artesunate (an artemisinin derivative) that kills malaria parasites through complementary mechanisms involving heme detoxification disruption and rapid parasite clearance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:48.538Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae"}]},"trialDetails":[{"nctId":"NCT05951595","phase":"PHASE3","title":"A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-11","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1680},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT05764746","phase":"PHASE2, PHASE3","title":"Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial","status":"RECRUITING","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2023-05-01","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":384},{"nctId":"NCT03640403","phase":"PHASE3","title":"Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania","status":"COMPLETED","sponsor":"National Institute for Medical Research, Tanzania","startDate":"2019-03-26","conditions":"Malaria,Falciparum, Anemia","enrollment":1555},{"nctId":"NCT06076213","phase":"PHASE4","title":"Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2023-05-01","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1260},{"nctId":"NCT05550909","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-10-17","conditions":"Malaria,Falciparum","enrollment":100},{"nctId":"NCT06300970","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-08-09","conditions":"Plasmodium Falciparum, Malaria, Uncomplicated Malaria","enrollment":352},{"nctId":"NCT04618523","phase":"PHASE4","title":"Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2020-10-26","conditions":"Malaria","enrollment":1117},{"nctId":"NCT02627456","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-09","conditions":"Malaria","enrollment":409},{"nctId":"NCT04829695","phase":"PHASE4","title":"Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon","status":"UNKNOWN","sponsor":"University of Yaounde 1","startDate":"2021-04-05","conditions":"Falciparum Malaria","enrollment":184},{"nctId":"NCT03773536","phase":"PHASE4","title":"Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2017-05-09","conditions":"Plasmodium Falciparum Malaria","enrollment":146},{"nctId":"NCT03768908","phase":"PHASE4","title":"Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2005-01-05","conditions":"Plasmodium Falciparum Malaria","enrollment":359},{"nctId":"NCT03764527","phase":"PHASE4","title":"Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2002-11-01","conditions":"Plasmodium Falciparum Malaria","enrollment":408},{"nctId":"NCT03431714","phase":"PHASE4","title":"Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania","status":"COMPLETED","sponsor":"National Institute for Medical Research, Tanzania","startDate":"2017-07-14","conditions":"Uncomplicated Falciparum Malaria","enrollment":333},{"nctId":"NCT02741024","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2013-10","conditions":"Malaria","enrollment":288},{"nctId":"NCT02637128","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-03","conditions":"MALARIA, FALCIPARUM","enrollment":452},{"nctId":"NCT00808951","phase":"PHASE4","title":"In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2008-12","conditions":"Malaria","enrollment":440},{"nctId":"NCT01697787","phase":"PHASE4","title":"Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2012-10","conditions":"Malaria","enrollment":150},{"nctId":"NCT01017770","phase":"PHASE4","title":"Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2008-09","conditions":"Uncomplicated P. Falciparum Malaria in Children","enrollment":340},{"nctId":"NCT01023399","phase":"PHASE4","title":"Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-11","conditions":"Malaria","enrollment":580},{"nctId":"NCT00393679","phase":"PHASE3","title":"Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2007-07","conditions":"Fever, Malaria","enrollment":4112},{"nctId":"NCT01378286","phase":"PHASE3","title":"Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-01","conditions":"Malaria","enrollment":380},{"nctId":"NCT01567423","phase":"NA","title":"Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria","status":"COMPLETED","sponsor":"Epicentre","startDate":"2008-04","conditions":"Malaria, Falciparum","enrollment":301},{"nctId":"NCT00374205","phase":"PHASE4","title":"Randomized Trial on Effectiveness of ACTs in Ghana","status":"TERMINATED","sponsor":"Bernhard Nocht Institute for Tropical Medicine","startDate":"2006-09","conditions":"Malaria, Falciparum","enrollment":245}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":103,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ASAQ","Camoquin","Coarsucam by Sanofi-Aventis","coarsucam"],"phase":"marketed","status":"active","brandName":"Amodiaquine-artesunate (ASAQ)","genericName":"Amodiaquine-artesunate (ASAQ)","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASAQ is a fixed-dose combination of amodiaquine (a 4-aminoquinoline) and artesunate (an artemisinin derivative) that kills malaria parasites through complementary mechanisms involving heme detoxification disruption and rapid parasite clearance. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}